Evaluation of the Efficacy of Intramuscular (IM) Administration of Ceftaroline (CPT) Against a Methicillin-Resistant Staphylococcus aureus (MRSA) Strain.

Slides:



Advertisements
Similar presentations
Monte Carlo simulations and bioequivalence of antimicrobial drugs NATIONAL VETERINARY S C H O O L T O U L O U S E July 2005 Didier Concordet.
Advertisements

POPULATION PHARMACOKINETICS OF CEFTRIAXONE IN INTENSIVE CARE UNIT (ICU) ADULT PATIENTS C Le Guellec (1), N Simon (2), D.Garot (3), R. Respaud (1), P Lanotte.
Scott Butler Infection Innovative Medicines Group AstraZeneca R&D, Boston CPTR Workshop, 2012 Arlington, VA AZD5847 Oxazolidinone for the treatment of.
Company: Cerexa Approval Status: November 2010Cerexa.
Poster will be available at after September 10 th 2006 ABSTRACT AN2690 is a new novel antifungal being developed for the treatment of onychomycosis.
Pharmacokinetics as a Tool
The innovative Swiss pharmaceutical company Mesporin: Mepha Health Care.. for Post-operative Infection.
PHL 424 Antimicrobials 9 th Lecture By Abdelkader Ashour, Ph.D. Phone:
Plasmids Chromosome Plasmid Plasmid + Transposon Plasmid + integron Plasmid+transposon +intergron Chromosome Chromosome + transposon Chromosome + transposon.
The Relationship between Daptomycin (DAP) Free drug AUC/MIC, Antibacterial effect (ABE) and Emergence of Resistance (EoR) in S.aureus. KE Bowker, AR Noel,
Pharmacokinetics Questions
Interchangeability and study design Drs. Jan Welink Training workshop: Training of BE assessors, Kiev, October 2009.
Laplace transformation
Gokaraju Rangaraju College of Pharmacy
Bioavailability of Drugs with Nonlinear Pharmacokinetics (PK) Can be Approximated by the Ratio of Doses that Provide Equal Areas under the Concentration-Time.
Office of Clinical Pharmacology and Biopharmaceutics IDSA/ISAP/FDA Workshop 4/16/04 In Vitro/Animal Models to Support Dosage Selection: FDA Perspective.
Carbapenem Activity Against Acinetobacter calcoaceticus-baumanii complex (ACBC) in an In Vitro Pharmacokinetic Bacteremia Model (PKM) Eric G Sahloff, Pharm.D.,
PK/PD of Antibiotics in relation to resistance Otto Cars MD Department of Medical Sciences Infectious diseases Uppsala University Sweden.
MethodsAbstract Methods Results Printed by Novel 8-Heterocyle Substituted Tetracyclines are Potent and Broad Spectrum Antibacterial Agents with Oral Bioavailability.
Week 6- Bioavailability and Bioequivalence
1 I4E-MC-JXBA and JXBB Phase 2 Study to Evaluate the PK and Drug-Drug Interaction of Cetuximab and Cisplatin (JXBA) Cetuximab and Cisplatin (JXBB)
Rational Dosing: The Use of Plasma Concentrations vs. Tissue Concentrations Hartmut Derendorf, PhD University of Florida.
Application of PK/PD modeling for optimization of linezolid therapy Julia Zayezdnaya Zack.
A New Approach to Determining Drug Schedules Helen Moore 1, Cherry Lei 2, and Nelson ‘Shasha’ Jumbe 1 1 Modeling & Simulation; 2 Non-clinical Biostatistics;
Pharmacodynamics of Antimicrobials in Animal Models William A. Craig, M.D. University of Wisconsin-Madison.
A Pharmacodynamic Model for Cefprozil against Haemphilus influenzae in an in vitro Infection Model across Multiple Regimens Olanrewaju O. Okusanya, Pharm.D,
INJECTAFER Pharmacokinetics (PK) and Pharmacodynamics (PD) Christy S. John, Ph.D Division of Clinical Pharmacology V Office of Clinical Pharmacology Division.
Area under the plasma concentration time curve. IMPORTANCE OF AUC Pharmacokinetics - measurement of bioavaibility absolute, relative Biopharmaceutics.
Multiple dosing: intravenous bolus administration
Animal Models in Early Evaluation of Antibacterial Agents
Continuous intravenous infusion (one-compartment model)
Pharmacodynamic Indices Canisius-Wilhelmina Hospital Nijmegen, The Netherlands Johan W Mouton.
Pk/Pd modelling : Clinical Implications
JWM Grindelwald Canisius-Wilhelmina Hospital, Nijmegen, The Netherlands Johan W. Mouton Pharmacodynamic Indices.
Pharmacokinetics (PK) and Pharmacodynamics (PD) of Rivaroxaban: A Comparison of Once- and Twice-daily Dosing in Patients Undergoing Total Hip Replacement.
REVISED ABSTRACT Background: Omadacycline (OMC) is the first of a new class of tetracyclines, the aminomethylcyclines, and is being developed as a once-daily.
Activities of Daptomycin (DAP), Vancomycin (VAN) and Linezolid (LDZ) alone or in combination with Fusidic acid (FUS) in an in vitro dynamic model of.
Figure 1: Mean comparative midazolam plasma concentration-time plot
Comparison of the intracellular and extracellular activities of approved and novel antistaphylococcal antibiotics using a pharmacodynamic model exploring.
Temocillin pharmacokinetics in healthy volunteers
Identification of optimal dose and dosing regimen of clofazimine for the treatment of multi-drug resistant tuberculosis (MDR-TB) based on pharmacokinetic.
The aminoglycoside antibiotics
Pharmacokinetics Tutoring
Miscellaneous Antibiotics
Abstract Results Methods Background Conclusions References
Pharmacokinetics Tutoring
Antibacterial Drugs General Terminology Mindy Valenti
1. Abstract 3. Objective of the study 4. Methods 5. Results
Correspondence: Bactericidal Activity of Fosfomycin against NDM-1 producing Enterobacteriaceae M. Albur, A. Noel, K. Bowker, A.
Introduction: Results: Methodology: Discussion: Conclusion:
F th Interscience Conference on Antimicrobial Agents and Chemotherapy October 25-28, Washington, DC The Activity of RTA-3, a Novel Antimicrobial.
Doripenem vs Meropenem: a summary of International and Belgian published data Françoise Van Bambeke, Unité de Pharmacologie cellulaire et moléculaire Louvain.
Activities of antistaphylococcal antibiotics towards the extracellular and intraphagocytic forms of Staphylococcus aureus isolates from a patient with.
P1257 Pharmacodynamics of Amikacin Inhale studied in an in vitro pharmacokinetic model of infection KE Bowker, AR Noel, SG Tomaselli, MLG Attwood, AP.
Françoise Van Bambeke, Dr Sc. Pharm, Agr. Ens. Sup.
The efficacy and safety of daptomycin: first in a new class of antibiotics for Gram- positive bacteria  M.J. Rybak  Clinical Microbiology and Infection 
Pharmacokinetics and pharmacodynamics of fluoroquinolones
J.-P. Stahl  Clinical Microbiology and Infection 
Activities of antistaphylococcal antibiotics towards the extracellular and intraphagocytic forms of Staphylococcus aureus isolates from a patient with.
Selected Bioavailability and Pharmacokinetic Calculations
P. Moreillon, J.M. Entenza  Clinical Microbiology and Infection 
Pharmacodynamic comparison of linezolid, teicoplanin and vancomycin against clinical isolates of Staphylococcus aureus and coagulase-negative staphylococci.
In-vivo impact of the MexXY efflux system on aminoglycoside efficacy in an experimental model of Pseudomonas aeruginosa pneumonia treated with tobramycin 
Plasma concentration–time profile, relative bioavailability and pharmacokinetic (PK) parameters of 4 mg TAK-228 in the single-agent QD PK run-in period,
Comparative bactericidal activities of daptomycin, glycopeptides, linezolid and tigecycline against blood isolates of Gram-positive bacteria in Taiwan 
P. Kaltsas, S. Want, J. Cohen  Clinical Microbiology and Infection 
Nanoemulsions as Versatile Formulations for Paclitaxel Delivery: Peroral and Dermal Delivery Studies in Rats  Sateesh Khandavilli, Ramesh Panchagnula 
Can pharmacokinetic–pharmacodynamic parameters provide dosing regimens that are less vulnerable to resistance?  P. Courvalin  Clinical Microbiology and.
Bactericidal activity and synergy studies of BAL9141, a novel pyrrolidinone-3- ylidenemethyl cephem, tested against streptococci, enterococci and methicillin-resistant.
J. Segreti  Clinical Microbiology and Infection 
Presentation transcript:

Evaluation of the Efficacy of Intramuscular (IM) Administration of Ceftaroline (CPT) Against a Methicillin-Resistant Staphylococcus aureus (MRSA) Strain in a Rabbit Endocarditis Model (REM) Contact Information – Request for reprint (PDF format) Cédric Jacqueline UPRES EA 3826 France Email: cedric.jacqueline@univ-nantes.fr C. Jacqueline,1 J. Caillon,1 V. Le Mabecque,1 E. Batard,1 A.F. Miegeville,1 D. Biek,2 Y. Ge,2 and G. Potel1 B-1003 1 UPRES EA 3826, UER Médecine, Nantes, France, and 2 Cerexa, Inc. Alameda, CA, USA. Abstract Methods Results Pharmacokinetics of Ceftaroline 20 mg/kg After IM Administration or Short IV Infusion Pharmacokinetics of Ceftaroline 20 mg/kg After IM Administration or Short IV Infusion After IM administration of 5-, 20-, and 40-mg/kg doses, the Cmax increased approximately in proportion to dose (5.18, 15.75, and 37.85 mg/L, respectively) and plasma half-life increasing from 0.74 to 1.14 hours (Figure 2). Background: Ceftaroline is a novel, parenteral, broad-spectrum cephalosporin exhibiting bactericidal activity against gram-positive organisms, including MRSA and multidrug-resistant Streptococcus pneumoniae (MDRSP), as well as common gram-negative pathogens. CPT is currently in phase 3 development. We previously reported the highly bactericidal activity of IV CPT against MRSA in rabbit. The objective of this study was to compare the activity of 3 different doses of CPT with teicoplanin (TEC) after IM administration against a MRSA strain using a REM. Methods: MICs were 1 and 0.5 mg/L for CPT and teicoplanin (TEC), respectively. Preliminary PK studies were performed to determine the PK parameters of IM administration and facilitate dose selection. Animals were randomized to: no treatment (controls), CPT 5 mg/kg bid, CPT 20 mg/kg bid, CPT 40 mg/kg bid, or TEC 20 mg/kg bid. Results: The absolute bioavailability of IM CPT exceeded 90% of IV CPT (as measured by AUC). The Cmax of CPT at 5, 20, and 40 mg/kg increased approximately in proportion to dose (5.18, 15.75, and 37.85 mg/L, respectively). The plasma elimination half-life was 0.74-1.14 hours over the range tested. See Table 1 for bacterial titers in vegetations after 4 days of treatment. Conclusions: IM CPT demonstrated excellent bactericidal activity against the MRSA strain at 20 and 40 mg/kg, resulting in sterilization rates in vegetations of 80% and 100%, respectively. The results strongly support IM CPT as a promising and effective therapeutic option for the treatment of severe MRSA infections. Figure 1. Ceftaroline fosamil is converted in vivo to the microbiologically active form, ceftaroline Discussion - Conclusion Using an infective endocarditis rabbit model, the %T>MICs attained with IM administration were associated with bactericidal activity against MRSA after a 4-day treatment. The efficacy of IM ceftaroline in the present study was similar to that achieved previously with IV ceftaroline administered in a regimen simulating the human dose (ie, 600 mg twice daily).2 As expected, teicoplanin 20 mg/kg IM displayed activity against the MRSA strain, with a sterilization rate of 60%. After a 4-day treatment regimen, IM ceftaroline demonstrated excellent bactericidal activity against the MRSA strain at 20-mg/kg and 40-mg/kg twice-daily doses in a rabbit endocarditis experimental model. These findings are consistent with a favorable IM pharmacokinetic profile and strongly support the development of IM ceftaroline as a promising and effective therapeutic option for the treatment of severe MRSA infections. Six animals were divided into 2 groups, and a 20-mg/kg dose of the prodrug ceftaroline acetate was administered by IM injection into the right thigh or by a very short (2-minute) IV infusion via the marginal ear vein. Blood samples were obtained from the animals through a catheter positioned in the median artery of the ear (contralateral to the ear used for drug administration in the IV group) over 8 hours (5, 10, 15, 30, and 45 minutes, and 1, 2, 4, and 8 hours post-dose). Samples were centrifuged for 10 minutes at 5000g, and plasma samples were frozen until bioassay. Results from the first phase of this investigation suggest that ceftaroline has an excellent pharmacokinetic profile after IM administration. Bioavailability of IM adminis tration exceeded 90% of IV infusion as calculated by area under the concentration-time curve (AUC) (Table 1). Cmax was decreased with IM administration compared with IV infusion as ceftaroline was slowly released from the IM injection site (Table I; Figure 2). In Vivo Activity of Ceftaroline After IM Administration The bacterial titers in vegetations following a 4-day treatment regimen for the 40 mg/kg, 20 mg/kg and 5 mg/kg doses of IM ceftaroline and IM teicoplanin are shown in Table II. The sterilization rate of vegetations produced by the MRSA strain are indicated in Figure 3. Ceftaroline fosamil Ceftaroline Figure 2. Ceftaroline concentrations after intramuscular (IM) and intravenous (IV) administration in the rabbit (mean ± standard deviation). Table I. Pharmacokinetic parameters following single-dose IM administration or short IV infusion of ceftaroline (mean ± standard deviation) ■ = 5-mg/kg IM dose ▲= 20-mg/kg IM dose ● = 40-mg/kg IM dose  = 20-mg/kg IV dose In Vivo Activity of Ceftaroline After IM Administration Pharmacokinetic parameter Ceftaroline 20 mg/kg IM administration IV administration Cmax (mg/L) 16.08 ± 0.69 84.03 ± 7.45 Tmax (minutes) 30 5 t1/2 (hours) 0.90 ± 0.28 0.18 ± 0.00 AUC0-8h (mg.h/L) 26.47 ± 2.89 29.16 ± 3.89 %T>MICa (8-h period) 46.3 ± 2.0 22.5 ± 1.9 %T>MICa (12-h period) 30.9 ± 1.3 15.0 ± 1.3 Using a well-established rabbit endocarditis model,1 experimental endocarditis was induced with an inoculum of 108 CFU of a MRSA strain with heterogeneous high-level methicillin resistance (methicillin MIC = 128 mg/L). Treatment was started 24 hours after inoculation and antibiotics (ceftaroline and teicoplanin) were administered twice daily using the IM route for 4 days. Animals (10 per group) were randomly assigned to no treatment (controls), ceftaroline 40 mg/kg IM twice daily, ceftaroline 20 mg/kg IM twice daily, ceftaroline 5 mg/kg IM twice daily, or teicoplanin 20 mg/kg IM twice daily. Introduction Ceftaroline, the bioactive metabolite of ceftaroline fosamil, is a novel, parenteral, broad-spectrum cephalosporin exhibiting bactericidal activity against gram-positive organisms, as well as gram-negative pathogens (Figure 1). The goals of our experiments were to compare the pharmacokinetic parameters of ceftaroline after IV and IM administration and evaluate the in vivo activity of 3 different doses of ceftaroline against MRSA compared with teicoplanin as a positive control after IM administration by using an aortic valve endocarditis rabbit model. Figure 3. Sterilization rate (%) of vegetation produced by the MRSA strain after 4 days of treatment a Methicillin-resistant Staphylococcus aureus strain with ceftaroline MIC = 1 mg/L References Table II. Bacterial titers in vegetations after 4 days of treatment Mean ± SD log10 CFU/g of vegetation (n) Controls 8.99 ± 0.47 (10) IM CPT (40 mg/kg bid) 2.45 ± 0.14 (10)a,c IM CPT (20 mg/kg bid) 3.14 ± 1.38 (10)a,b IM CPT (5 mg/kg bid) 5.26 ± 2.73 (9)a IM TEC (20 mg/kg bid) 3.07 ± 0.66 (10)a,b Durack, D.T., and P.B. Beeson. 1972. Experimental bacterial endocarditis, II: survival of a bacteria in endocardial vegetations. Br. J. Exp. Pathol. 53:50-53. Jacqueline, C., J. Caillon, V. Le Mabecque, et al. In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model. Antimicrob. Agents Chemother. 2007;51:3397-3400. (n): no. of animals; a: P < 0.001 vs controls; b: P < 0.05 vs IM CPT (5 mg/kg bid); c: P < 0.001 vs IM CPT (5 mg/kg bid); Bonferroni’s test after analysis of variance.